Last reviewed · How we verify
Usual antibiotic treatment
This drug inhibits bacterial cell wall synthesis.
This drug inhibits bacterial cell wall synthesis. Used for Community-acquired pneumonia, Skin and soft tissue infections.
At a glance
| Generic name | Usual antibiotic treatment |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Beta-lactam antibiotic |
| Target | Penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious disease |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to penicillin-binding proteins, which are essential for bacterial cell wall formation. This leads to weakened cell walls and ultimately bacterial cell death.
Approved indications
- Community-acquired pneumonia
- Skin and soft tissue infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Dizziness
- Fatigue
- Rash
- Allergic reactions
- Seizures
Key clinical trials
- Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children (NA)
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia (NA)
- Enhanced Recovery After Surgery (ERAS) in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery With or Without HIPEC (NA)
- The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) (NA)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Corticosteroid Treatment in OLP (NA)
- TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): a Stepped-Wedge Cluster Randomized Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Usual antibiotic treatment CI brief — competitive landscape report
- Usual antibiotic treatment updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI